Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
Following consideration of a resubmission, the Scottish Medicines Consortium (SMC) still does not recommend dexamethasone intravitreal implant (Ozurdex®) for use within NHS Scotland for the treatment of adult patients with macular oedema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
The drug advice (see link below) notes that the 700mcg Ozurdex® implant was superior to sham in two Phase III studies, in terms of the proportion of patients with a best corrected visual acuity improvement at 90 days following treatment. Longer-term effectiveness of treatment is however uncertain. The SMC was unable to recommend its use as the company did not provide a sufficiently robust clinical and economic analysis. The licence holder has indicated their intention to resubmit.
Uncategorized